Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation

Fineline Cube May 8, 2026
Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Legal / IP Policy / Regulatory

China’s Seven Ministries Issue Revised Pharmaceutical Representative Management Measures to Combat Commercial Bribery and Strengthen Industry Oversight

Fineline Cube May 8, 2026
Company Drug

Wuhan YZY Biopharma’s Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment

Fineline Cube May 8, 2026
Company Drug

Guangdong Zhongsheng Pharma Reports Positive Phase IIb Results for First-in-Class ZSP1601 in Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis Reversal Potential

Fineline Cube May 8, 2026
Company Medical Device

Sansure Biotech Secures CE Mark for 60 Molecular Diagnostic Products, Including Procalcitonin Assay Kit

Fineline Cube Sep 22, 2023

Sansure Biotech Inc., a leading molecular diagnostics specialist based in China (SHA: 688289), has announced...

Company Deals

Abbott Expands Biosimilars Portfolio with mAbxience In-License Agreement

Fineline Cube Sep 21, 2023

Abbott (NYSE: ABT) has announced the in-licensing of several biosimilar drugs from Spain-based biotechnology firm...

Company Deals

Merck Forges Partnerships with BenevolentAI and Exscientia for Precision Drug Discovery

Fineline Cube Sep 21, 2023

German pharmaceutical company Merck (NYSE: MRK) has announced two separate strategic collaborations with UK-based artificial...

Company Drug

Novartis’s Aimovig Approved by China’s NMPA for Preventive Migraines Treatment

Fineline Cube Sep 21, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that it has received market approval from...

Company Drug

Organon’s Liptruzet Approved in China for Hypercholesterolemia Treatment

Fineline Cube Sep 21, 2023

US-based Organon (NYSE: OGN) has announced that it has received market approval from the National...

Company

WuXi XDC Expands Manufacturing Capacity with New GMP Facilities in Wuxi

Fineline Cube Sep 21, 2023

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...

Policy / Regulatory

CDE Releases 74th Batch of Generic Reference Preparations with 58 New Specifications

Fineline Cube Sep 21, 2023

The Center for Drug Evaluation (CDE) has released the 74th batch of chemical generic reference...

Company Deals

Roche’s Genentech Partners with Peptidream for First-in-Class PDCs in Radioisotope Therapy

Fineline Cube Sep 21, 2023

Swiss pharmaceutical giant Roche’s subsidiary, Genentech (SWX: ROG), has announced a partnership with Japan’s peptide-based...

Company Deals

Lynk Pharmaceuticals Secures Series C2 Financing to Advance pipeline

Fineline Cube Sep 21, 2023

Lynk Pharmaceuticals Co., Ltd, a China-based pharmaceutical company, has announced the successful completion of its...

Company Drug

Hainan Poly Pharm Submits DMF for Tecovirimat API to US FDA

Fineline Cube Sep 21, 2023

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced the filing of a Drug...

Company Legal / IP

South Africa’s Competition Commission Investigates J&J for MDR-TB Drug Pricing and Evergreening

Fineline Cube Sep 21, 2023

The Competition Commission of South Africa has announced an investigation into Johnson & Johnson (J&J;...

Company Drug

Tonghua Golden-Horse’s Octohydroaminoacridine Succinate Meets Phase III Endpoints in Alzheimer’s Disease

Fineline Cube Sep 21, 2023

China-based Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. (SHE: 000766) has announced positive results from its...

Policy / Regulatory

China’s NHC Expands Rare Disease List, Includes 21 Cancer Types

Fineline Cube Sep 21, 2023

The National Health Commission (NHC) of China has released an updated national list of rare...

Company Drug

AIM Vaccine’s Serum-Free Rabies Vaccine Completes Phase III Safety Observation

Fineline Cube Sep 21, 2023

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the successful completion of the 7-day...

Company Drug Medical Device

Jiangsu Yahong’s Cevira Meets Primary Endpoint in Phase III Cervical HSIL Study

Fineline Cube Sep 21, 2023

Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176), a specialist in urogenital cancer treatments, has...

Company Drug

Hybio Pharmaceutical Gets NMPA Approval for COVID-19 Nasal Spray HY3000

Fineline Cube Sep 21, 2023

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has received approval from the National Medical Products...

Company Drug

GSK’s Ojjaara Approved by FDA for Anemic Myelofibrosis Patients

Fineline Cube Sep 20, 2023

The US Food and Drug Administration (FDA) has granted regulatory approval to GlaxoSmithKline (GSK; NYSE:...

Company Drug

BeiGene Regains Full Rights to Tislelizumab After Terminating Novartis Deal

Fineline Cube Sep 20, 2023

China-based biotech company BeiGene (NASDAQ: BGNE) has reached a mutual agreement with Novartis (NYSE: NVS)...

Company

Kinnate Biopharma Announces Restructuring and Job Cuts Amid Financial Pressures

Fineline Cube Sep 20, 2023

US-based Kinnate Biopharma Inc., (NASDAQ: KNTE), a company dedicated to the development of small-molecule cancer...

Company Drug

Jiangsu Hengrui Pharmaceuticals Wins NMPA Approval for Two Novel Drug Candidates

Fineline Cube Sep 20, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, has announced receiving...

Posts pagination

1 … 465 466 467 … 662

Recent updates

  • Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance
  • Zai Lab Reports Q1 2026 Revenue Decline Amid Zejula Impact from Centralized Procurement, Offset by Xacduro Growth
  • Viatris Reports 8% Revenue Growth in Q1 2026 Fueled by Greater China Surge and Brand Portfolio Strength
  • Gilead Sciences Reports 4% Revenue Growth in Q1 2026 Driven by HIV Portfolio Strength and Trodelvy Expansion
  • Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance

Company

Zai Lab Reports Q1 2026 Revenue Decline Amid Zejula Impact from Centralized Procurement, Offset by Xacduro Growth

Company

Viatris Reports 8% Revenue Growth in Q1 2026 Fueled by Greater China Surge and Brand Portfolio Strength

Company

Gilead Sciences Reports 4% Revenue Growth in Q1 2026 Driven by HIV Portfolio Strength and Trodelvy Expansion

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.